Cash and cash equivalents were $44.7M as of December 31, 2023, compared to $120.4M as of December 31, 2022. “With our recently announced partnership with Gilead for XTX301, our tumor-activated IL-12, and additional financing from existing investors, we believe we are well-positioned to continue to advance our differentiated pipeline of tumor-activated I-O therapies and achieve potential near-term clinical milestones and value-drivers,” said Rene Russo, Pharm.D., president and chief executive officer of Xilio. “Looking ahead, we are focused on rapidly advancing clinical development for XTX301 and XTX101, our tumor-activated, Fc-enhanced anti-CTLA-4, with anticipated clinical data for each of these programs later this year, as well as continuing to leverage our novel research platform to design and develop tumor-activated bispecific and immune cell engager molecules.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XLO:
- Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
- Xilio Therapeutics Strikes Lucrative Deal with Gilead Sciences
- Gilead sees FY24 EPS reduction of 3c-4c from Xilio Therapeutics deal
- Xilio Therapeutics, Gilead announce exclusive license agreement for XTX301
- Xilio Therapeutics announces $11.3M private placement equity financing